Prostate Cancer Hypofractionated Radiation Therapy Report Quality of Life

Prostate cancer patients who received hypofractionated (HPFX) radiation therapy (RT) reported that their quality of life, as well as bladder and bowel function, were at similar levels before and after RT, according to research presented at the American Society for Radiation Oncology’s (ASTRO’s) 56th Annual Meeting. 

September 15, 2014 — A comparison of five-year sexual function outcomes, as reported by patients treated with external beam radiation therapy (EBRT) versus combination EBRT plus brachytherapy, indicates the utilization of vessel-sparing radiation therapy makes cure possible without compromising long-term sexual function, according to research presented today at ASTRO 2014.

September 15, 2014 — The American Society for Radiation Oncology (ASTRO) released its second list of five radiation oncology-specific treatments that are commonly ordered but may not always be appropriate, as part of the national Choosing Wisely campaign, an initiative of the ABIM Foundation.

September 15, 2014 — The American Association of Neurological Surgeons (AANS) and the American Society for Radiation Oncology (ASTRO) announced they are partnering to launch and support a national registry for stereotactic radiosurgery (SRS) treatments.

September 15, 2014 — A secondary analysis of the National Surgical Adjuvant Breast and Bowel Project B-32 trial (Krag 2010) indicates that radiation therapy does not increase the incidence of lymphedema in patients with node-negative breast cancer, according to research presented this week at the 56th annual meeting of the American Society for Radiation Oncology (ASTRO).

High-risk prostate cancer patients who receive radiation therapy and an 18-month course of androgen deprivation therapy recover a normal testosterone level in a shorter amount of time compared to those who receive a 36-month course of ADT, thus resulting in a better quality of life and without detriment to long-term outcomes, according to research presented at ASTRO 2014.

Manuka Honey Pain Reduction Radiation-enduced Esophagitis Lung Cancer

Patient-reported data indicates that when Manuka honey is prescribed for esophagitis pain during radiation therapy (RT), it is not more effective than standard medical care, according to research presented at the American Society for Radiation Oncology’s (ASTRO’s) 56th Annual Meeting.

Patients with stage I and II Hodgkin’s Disease who receive consolidated radiation therapy (RT) have a higher 10-year survival rate of 84 percent, compared to 76 percent for patients who did not receive RT; and, the data also shows a decrease in utilization of RT, according to research presented today at the American Society for Radiation Oncology’s (ASTRO’s) 56th Annual Meeting.
Radiation Therapy Esophageal Cancer ASTRO 2015

Radiation therapy (RT) alone is as effective in decreasing swallowing complications experienced by advanced esophageal cancer patients as RT combined with chemotherapy, thus allowing patients to forgo chemotherapy, according to research presented today at the American Society for Radiation Oncology’s (ASTRO’s) 56th Annual Meeting.

September 12, 2014 — Civco Medical Solutions will be featuring an expansive solution lineup at the upcoming annual meeting of the American Society for Radiation Oncology (ASTRO) in San Francisco, including more advanced patient positioning options for stereotactic body radiation therapy (SBRT) and SRS/SRT (stereotactic radiosurgery/stereotactic radiotherapy) treatments.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now